**Appendix Table D9. Strength of evidence of reduction of baseline migraine frequency by >50%with antiepileptic topiramate in children (results from randomized controlled clinical trials)7, 8**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Dose** | **Rate, %**  **Drug**  **[placebo]** | **RCTs** | **Children** | **Directness** | **Risk of bias** | **Consistency** | **Precision** | **Dose response** | **Strength of evidence** | **Conclusion** |
| 100-200mg/day | 61.2 [45.8] | 2 | 230 | Yes | Medium | Yes | Yes | Not applicable | Moderate | Topiramate, 100-200mg/day, did not increase rate of reduction in migraine by ≥50% |
| 50mg/day | 45.7 [45.5] | 1 | 68 | Yes | Low | NA | Yes | Not applicable | Low | Topiramate, 50mg/day, did not increase rate of reduction in migraine by ≥50% |
| 50-200mg/day | 58.2 [45.7] | 2 | 298 | Yes | Medium | Yes | Yes | No | Moderate | Topiramate, 50-200mg/day, did not increase rate of reduction in migraine by ≥50% |